Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · Real-Time Price · USD
1.030
-0.080 (-7.21%)
At close: Nov 7, 2024, 4:00 PM
1.080
+0.050 (4.85%)
After-hours: Nov 7, 2024, 6:07 PM EST
Carisma Therapeutics Stock Forecast
CARM's stock price has decreased by -66.55% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for CARM stock have an average target of 12.67, with a low estimate of 6.00 and a high estimate of 24. The average target predicts an increase of 1,130.10% from the current stock price of 1.03.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CARM stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| EF Hutton | EF Hutton | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +2,230.10% | Nov 7, 2024 |
| EF Hutton | EF Hutton | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +2,230.10% | Oct 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +676.70% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +676.70% | Jun 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +676.70% | May 17, 2024 |
Financial Forecast
Revenue This Year
22.98M
from 14.92M
Increased by 54.05%
Revenue Next Year
17.14M
from 22.98M
Decreased by -25.44%
EPS This Year
-1.23
from -2.59
EPS Next Year
-1.27
from -1.23
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 30.0M | 21.0M | 21.0M | ||
| Avg | 23.0M | 17.1M | 20.4M | ||
| Low | 19.0M | 13.3M | 19.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 101.3% | -8.6% | 22.5% | ||
| Avg | 54.0% | -25.4% | 19.0% | ||
| Low | 27.4% | -42.0% | 14.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.80 | -0.62 | -0.62 | ||
| Avg | -1.23 | -1.27 | -1.38 | ||
| Low | -1.50 | -1.74 | -2.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.